MDM2, MDMX and p53 in oncogenesis and cancer therapy
Top Cited Papers
- 10 January 2013
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 13 (2) , 83-96
Abstract
MDM2 and MDMX are RING domain proteins that exert their oncogenic effects primarily by inhibiting the p53 tumour suppressor protein. Each protein is overexpressed in diverse tumour types by mechanisms including gene amplification and post-translational stabilization; this is generally more frequent in tumours with a wild-type TP53 allele. Despite their similar structures, only MDM2 has intrinsic E3 ubiquitin ligase activity. Although MDM2 alone can inhibit p53, its RING-dependent heterodimerization with MDMX has an important role in p53 inhibition. Both MDM2 and MDMX interact with multiple other partners. Aberrant interactions with these partners may also affect gene expression and genome stability. Structure-based drug design has yielded several MDM antagonists that block MDM–p53 interactions, leading to p53 activation. At least one agent has progressed to clinical trials. Systems biology studies are providing the rationale for using MDM protein antagonists in combination with both approved and experimental pathway-targeted anticancer drugs.Keywords
This publication has 173 references indexed in Scilit:
- ATM Phosphorylation of Mdm2 Ser394 Regulates the Amplitude and Duration of the DNA Damage Response in MiceCancer Cell, 2012
- Deconstructing p53 transcriptional networks in tumor suppressionTrends in Cell Biology, 2012
- Carcinogen-induced hepatic tumors in KLF6+/− mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulationHepatology, 2011
- A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53Cancer Cell, 2010
- RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma DevelopmentCancer Cell, 2010
- A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor DevelopmentCancer Cell, 2010
- The p53 orchestra: Mdm2 and Mdmx set the toneTrends in Cell Biology, 2010
- p53-Mediated Hematopoietic Stem and Progenitor Cell CompetitionCell Stem Cell, 2010
- A survey of glioblastoma genomic amplifications and deletionsJournal of Neuro-Oncology, 2009
- Increased Radioresistance and Accelerated B Cell Lymphomas in Mice with Mdmx Mutations that Prevent Modifications by DNA-Damage-Activated KinasesCancer Cell, 2009